n°256

February 2024

Issue Contents
Editorial

Free  Leave my placenta alone!

p.31

Marketing Authorisations


Birch bark extract cutaneous gel (Filsuvez°) in epidermolysis bullosa

p.33-35

Olaparib (Lynparza°) as adjuvant treatment for certain breast cancers with a BRCA mutation

p.35-36

Olaparib (Lynparza°) as "maintenance" therapy for certain advanced ovarian cancers after first-line chemotherapy

p.37-38

Editors' opinion. New data

p.38

Avalglucosidase alfa (Nexviadyme°) in Pompe disease

p.39-40

Asciminib (Scemblix°) in chronic myeloid leukaemia

p.41

Teclistamab (Tecvayli°) in multiple myeloma after several lines of treatment

p.42

Brolucizumab (Beovu°) in diabetic macular oedema

p.43

Ambrisentan (Volibris° or other brands) in pulmonary arterial hypertension from 8 years of age

p.44

Pembrolizumab (Keytruda°) as second- or subsequent-line treatment for various cancers with DNA repair defects

p.44

Editors' opinion. Another marketing authorisation based on an unethical evaluation!

p.45

Sublingual sufentanil (Dzuveo°) for acute pain

p.45-46

Adverse Effects


Drugs that interfere with the placenta and affect the fetus

p.47

Clomifene: serious, sometimes irreversible, vision disorders

p.48

Crizotinib and sofosbuvir + velpatasvir: increased risk of heart failure and bradycardia

p.48

Cyproheptadine to gain weight: a high-risk use

p.49

Common stem: -fentanil

p.49

Outlook


Free  Towards better patient care: drugs to avoid in 2024

p.50-53

Inset. Main changes in the 2024 update of Prescrire's drugs to avoid

p.52

Free  European Commission: taken to task by the Ombudsman for lack of transparency

p.54

Free  Revision of European pharmaceutical legislation

p.55

Masthead


Free  Masthead

p.30

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe